Podcast 17 Nov 2023How can life-saving vaccines be more affordable? Phenotypeca, a biotech business from Nottingham, UK, has been working with the Bill & Melinda Gates Foundation to produce albumin for low and middle-income countries (LMICs), offering a catalyst for making life-saving vaccines affordable globally. Global vaccine production faces several challenges. Limited availability and the high costs associated with recombinant albumin act as a barrier […] November 17, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 6 Nov 2023 The biggest private biotech investments in October 2023 The companies Aiolos Bio, MapLight Therapeutics and Agomab Therapeutics bagged the biggest biotech investments in October 2023. Around the world, biomaterials, central nervous system and musculoskeletal disorder players attracted the most investor interest. October 2023 saw a lot of fundraising taking place both in and out of healthcare in the U.S. and Europe. However, the […] November 6, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Oct 2023 The biggest private biotech investments in September 2023 The companies Generate Biomedicines, Apollo Therapeutics and Nimbus Therapeutics bagged the biggest biotech investments in September 2023. Around the world, drug discovery and oncology players attracted the biggest funding rounds. As we made our way into autumn in the Northern Hemisphere, September 2023 saw some big funding rounds take place around the globe, particularly within […] October 9, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2023 Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities The U.K. is rejoining the European Union’s (EU’s) $100 billion research program Horizon Europe, after being locked out of the deal amid post Brexit tensions for more than two years. This comes after months of negotiations between the U.K. government and the EU, in an attempt to broaden opportunities for researchers in the U.K.. British […] September 18, 2023 - 5 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 4 Sep 2023 The biggest private biotech investments in August 2023 The companies Genesis Therapeutics, ADARx Pharmaceuticals, and Abcuro bagged the biggest biotech investments in August 2023. Around the world, companies focused on immunology, genetic disorders, and metabolic disorders attracted the biggest funding rounds. Overall, quite a lot of biotech fundraising took place in August 2023. As always, there were some big rounds within the U.S. […] September 4, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Aug 2023 Are these 10 biotech recruiters on your radar this year? The process of hunting for recruits can be a struggle for many companies, particularly when they have an ideal candidate in mind. And many at times, for the life science/biotech industry, due to the highly competitive landscape – for both recruiters and job seekers – hiring has been made more difficult. While some believe that […] August 29, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 25 Aug 2023Beyond Biotech podcast 60 – The cost of research On this week’s podcast, we have a conversation with Dr Jack Scannell, CEO of Etheros Pharmaceuticals Corp. Scannell recently co-authored a paper on the expenses related to clinical research and the factors that underly the translational failure of inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) in oncology. Costs and Causes of Oncology Drug Attrition […] August 25, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 9 Aug 2023 Meet the startup working to help treat a rare pediatric cancer Nearly 50% of the children diagnosed with neuroblastoma are considered high-risk, where the tumor has spread, making surgery no longer a viable treatment option. Owing to this stark statistic, the disease is quite difficult to treat. But there might be light at the end of the tunnel. U.K.-based Renaissance Pharma’s drug candidate, which has shown […] August 9, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 NK:IO awarded £1.6M grant to develop NK cell therapy NK:IO, a U.K. company working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, has been awarded £1.6 million ($2.1 million) in grant funding from Innovate UK’s New Cancer Therapeutics program. The funding will support preclinical development, including development of a manufacturing process in collaboration […] July 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 Alchemab Therapeutics unveils Alzheimer’s candidate Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France. ATLX-1088 is a potential first-in-class human antibody targeting CD33, a cell surface protein thought to have a key role in Alzheimer’s disease. […] June 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 Ovarian cancer study finds key genes for potential treatments New study is increasing knowledge of why some women with the most lethal form of ovarian cancer respond much better to treatment than others. Researchers at Imperial College London in the U.K. have confirmed that the tumors of some women with high-grade serious ovarian cancer (HGSOC) contain a type of lymphoid tissue – known as […] June 22, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 NodThera announces positive inflammatory disease data NodThera has announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796. In the studies, both candidates were shown to clearly inhibit the NLRP3 inflammasome, a highly validated drug target that plays a pivotal role in controlling inflammatory diseases. The differentiated design characteristics of each candidate enabled them to penetrate different […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email